Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002683853 | SCV003720451 | uncertain significance | Inborn genetic diseases | 2022-05-30 | criteria provided, single submitter | clinical testing | The c.3626G>A (p.R1209Q) alteration is located in exon 25 (coding exon 25) of the PIEZO1 gene. This alteration results from a G to A substitution at nucleotide position 3626, causing the arginine (R) at amino acid position 1209 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV003135269 | SCV003812999 | uncertain significance | not provided | 2022-01-06 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003135269 | SCV004262073 | benign | not provided | 2023-07-04 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV003135269 | SCV004562725 | likely benign | not provided | 2023-04-14 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV003135269 | SCV005412543 | uncertain significance | not provided | 2023-10-24 | criteria provided, single submitter | clinical testing | BP4_strong |